Covid-19 roundup: BioNTech going head-to-head with Moderna as PhIII mRNA launch looms; Trial on Shinzo Abe’s once-favorite antiviral is inconclusive
It’s a race to the Phase III finish line now for the 2 leading mRNA vaccines in the pipeline for Covid-19.
BioNTech chief Ugur Sahin …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.